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ABSTRACT 
Extracellular vesicles (EVs) are membrane-bound intercellular communication 
vehicles that transport proteins, lipids and nucleic acids with regulatory capacity 
between cells. RNA profiling using microarrays and sequencing technologies has 
revolutionized the discovery of EV-RNA content, which is crucial to understand the 
molecular mechanism of EV function. Recent studies have indicated that EVs are 
enriched with specific RNAs compared to the originating cells suggestive of an active 
sorting mechanism. Here, we present the comparative transcriptome analysis of 
human osteoblasts and their corresponding EVs using next-generation sequencing. 
We demonstrate that osteoblast-EVs are specifically depleted of cellular mRNAs that 
encode proteins involved in basic cellular activities, such as cytoskeletal functions, 
cell survival and apoptosis. In contrast, EVs are significantly enriched with 254 
mRNAs that are associated with protein translation and RNA processing. Moreover, 
mRNAs enriched in EVs encode proteins important for communication with the 
neighboring cells, in particular with osteoclasts, adipocytes and hematopoietic stem 
cells. These findings provide the foundation for understanding the molecular 
mechanism and function of EV-mediated interactions between osteoblasts and the 
surrounding bone microenvironment.  
Keywords: Extracellular vesicles; Intercellular communication; Osteoblasts; 
Extracellular mRNA; Next-generation sequencing 
Abbreviations: 
EV: Extracellular vesicles 
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1. Introduction 
 
Extracellular RNAs have long been utilized as non-invasive tools for early 
diagnosis of clinical disorders [1, 2]. More recently, various studies reported RNA 
transfer between cells providing cues to their biological significance [3, 4]. The 
majority of extracellular RNA is found in tight complexes with proteins or lipids, as a 
protection against the action of RNases present in the circulation [5, 6]. The discovery 
of extracellular RNA with regulatory capacity packaged inside extracellular vesicles 
(EVs) provided a key indication for EVs as a novel mode of communication between 
cells [7-9].  
 
EVs are actively secreted small membrane-bound structures consisting of a 
lipid bilayer enclosing a lumen that contains a bioactive message in forms of lipids, 
proteins and nucleic acids [10-12]. Extensive studies of EVs present in cell culture 
media or biological fluids revealed that EVs are very heterogeneous in size (10 nm to 
5 μm) and morphology. Most often they are classified in at least three categories, such 
as exosomes, microvesicles and apoptotic bodies, merely based on their biogenesis. 
Their specific structure is essential for the protection of the vesicular cargo in the 
extracellular environment until they reach the target cells, where they regulate a broad 
range of biological functions [13-15]. Advanced high throughput RNA and protein 
analysis methods (‘omics’ technologies) have greatly facilitated the characterization 
of EV content and our ability to understand EV function. Since the first discovery of 
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EV-associated RNA, many studies have focused on delineating the EV-RNA profile 
[16-18]. Interestingly, EVs are devoid of cellular ribosomal RNA (rRNA), and instead 
are enriched with small RNA molecules. This selective enrichment of RNA species 
suggests that RNA enters EV through active sorting rather than random incorporation 
as a by-product of cell death [8]. Moreover, distinct EV-RNA patterns are evident in 
EVs from different cellular sources emphasizing the specificity of cargo loading in 
EVs. Expression profiling studies focusing on mRNA and microRNA (miRNA) 
analysis by next-generation sequencing or microarray analyses have shown that 
numerous small non-coding RNA molecules (e.g. small nuclear RNAs, vault RNA, Y 
RNA) are present inside EVs [19-21]. At present, there is a significant body of 
evidence indicating that EV-RNAs are important for development, immunology, 
angiogenesis, stem cell biology, and cancer, among many other biological functions 
[22-25].  
 
Osteoblasts are specialized bone cells that are responsible for the formation of 
mineralized bone tissue. Yet, these cells also play pivotal roles in maintaining cellular 
homeostasis by regulating interactions with surrounding cells [26-28]. Previously, we 
showed that osteoblasts secrete EVs packaged with functional proteins that contribute 
to the complex network of communication with the cells in the osteoblastic 
microenvironment [29]. The crosstalk is also highly regulated at the level of gene 
expression. In the present study, we employed next-generation sequencing analysis 
for in-depth characterization of the mRNA content of EVs that are secreted by human 
osteoblasts. Using a bioinformatics workflow, we described mRNA species that are 
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selectively incorporated into EVs or depleted from EVs during their biogenesis, and 
explored the molecular functions by which osteoblasts may deliver their specific 
regulatory message. Our comprehensive transcriptome profiling represents a versatile 
resource for diverse biomedical applications ranging from biomarker discovery to 
gene therapy.  
 
2. Materials and methods 
 
2.1. Cell culture and EV isolation  
 
Simian virus 40-immortalized human osteoblast cells (SV-HFO cells) were cultured 
under non-mineralizing conditions in α-MEM (GIBCO, Paisley, UK) supplemented 
with 20 mM HEPES, pH 7.5 (Sigma, St. Louis, MO, USA), streptomycin/ penicillin, 
1.8 mM CaCl2 (Sigma), 10 mM β-glycerophosphate (Sigma) and 2% depleted 
(100,000g for 90 minutes at 4°C)-FCS (GIBCO) at 37°C in a humidified atmosphere 
of 5% CO2 for 14 days. The culture medium was replaced every 2-3 days. SV-HFOs 
were washed with 1X PBS and refreshed with serum-free medium 24 hours prior to 
EV isolation. EVs were isolated from SV-HFO conditioned medium by low speed 
centrifugation (1,500 rpm, 5 minutes; 4,500 rpm, 10 minutes) followed by 
ultracentrifugation (20,000g, 30 minutes; 100,000g, 1 hour at 4°C) using the SW32Ti 
rotor (Beckman Coulter, Fullerton, CA, USA).  
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2.2. RNA isolation and quantitative real-time PCR 
 
Total cellular and EV-RNA was isolated using the TRIzol® reagent (Thermo Fisher 
Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. RNA 
concentration was determined using Nanodrop (Thermo Fisher Scientific) and size 
distribution was checked on an Agilent Bioanalyzer RNA 6000 Nano chip (Thermo 
Fisher Scientific). Quantitative real-time PCR was performed using the SYBR
TM
 
Green kit (Eurogentec, Seraing, Belgium) according to the manufacturer’s 
instructions. The primer sequences are listed in supplementary information. 
 
2.3. Next-generation sequencing and bioinformatics analysis 
 
RNA sequencing and bioinformatic analysis was performed as previously described 
[30]. In brief, sequencing RNA libraries were prepared with the TruSeq RNA Sample 
Prep Kit v2 (Illumina, San Diego, CA, USA) according to the manufacturer’s 
instructions. The concentration and size distribution of the libraries was determined 
on an Agilent Bioanalyzer DNA 1000 chip (Thermo Fisher Scientific), and verified 
with Qubit fluorometry (Thermo Fisher Scientific). Libraries were loaded onto flow 
cells at concentrations of 8–10 pM to generate cluster densities of 700,000/ mm2 
following the standard protocol for the Illumina cBot and cBot Paired-end cluster kit 
version 3. Flow cells were sequenced as 51 × 2 paired end reads on an Illumina HiSeq 
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2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection 
software. Base-calling was performed using Illumina's RTA version 1.17.21.3. The 
sequencing data are available in the Gene Expression Omnibus (GEO) database 
repository (https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE85761. 
The sequencing data was analyzed using MAPRSeq v1.2.1 system. Normalization 
(counts per million mapped reads, CPM; and reads per kilobasepair per million 
mapped reads, RPKM) analysis was performed using edgeR 2.6.2. The data from the 
replicates were combined as averages of the normalized read values, and only 
transcripts with CPM ≥ 1 for all replicates were included in the analysis. Comparative 
analyses of the EV data were obtained by querying the Vesiclepedia plugin provided 
by FunRich functional enrichment analysis tool (V2.1.2, 29 April 2015). IPA 
(Ingenuity® Systems, www.ingenuity.com) was used to classify the mRNA 
categories and predict target pathways and genes. DAVID Bionformatics Resources 
v6.7 was used to categorize the genes into overrepresented processes using human 
genome as a background [31].  
 
2.4. Statistics 
 
The data provided were based on multiple independent experiments. The results were 
described as mean ± SD. Significance was calculated using paired Student’s t-test, 
and P values of < 0.05 were considered significant.  
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3. Results 
 
3.1. Osteoblasts secrete RNA containing EVs  
 
To characterize the transcriptome of EVs, we isolated RNAs present in EVs 
released by human osteoblastic cells (SV-HFOs) at day 12-14 of their maturation. We 
isolated EVs using a step-wise differential ultracentrifugation protocol, and isolated 
total EV-RNA using the TRIzol® extraction method. Quality control of RNA samples 
revealed that the yield is consistent between the independent EV preparations, with an 
average of 2.6 μg EV-RNA deriving from 80 ml of culture medium. In parallel, we 
also isolated total RNA from the same osteoblasts to permit a direct comparison of 
RNA content. Representative Bioanalyzer electropherograms show expected 
differences in the RNA size distribution profiles for osteoblasts and their 
corresponding EVs (Fig. 1a,b).  EVs mainly contain small RNAs with a size range 
between 25 and 1,000 nucleotides, and lack the intact rRNA peaks characteristic of 
cellular 18S and 28S rRNAs. These findings emphasize the robustness of our isolation 
techniques and clearly demonstrate the distinctiveness of EV-RNA content compared 
to their parental cells. 
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3.2. EV-mRNA profiling using next-generation sequencing 
 
We investigated the EV-mRNA profile at high resolution by next-generation 
sequencing. We constructed sequencing libraries from three independent osteoblast 
cultures and their derived EVs, and analyzed the data using an established 
bioinformatics workflow (Fig. 2).  
 
The detected RNA read counts are robust and reproducible between the 
sequencing libraries, indicating a consistent distribution across independent 
preparations (Supplementary Table 1). Scatter plot analysis shows a fairly strong 
positive correlation between cellular RNA and EV-RNA (R
2
: 0.731, P < 0.0001) (Fig. 
3a). The majority of the sequencing reads are mapped to mRNA sequences for both 
osteoblasts (11,714 mRNAs) and EVs (11,629 mRNAs) (Fig. 3b). Classification of 
cellular- and EV-mRNAs shows a high diversity of biochemical functions (Fig. 3c). 
 
As it is evident from the scatter plot, the majority of the mRNAs are shared 
between osteoblasts and EVs. Yet, a small but significant fraction of mRNAs is 
exclusive to either osteoblasts or EVs [5.9% (693 mRNAs) and 5.2% (608 mRNAs), 
respectively] (Fig. 4a). These exclusive mRNAs are expressed at relatively low levels 
and represent a small fraction of total cellular- and EV-mRNA read counts (0.16% 
and 0.17%, respectively).  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
 
 
 Morhayim et al. 
 
 
 
 
10 
Interestingly, the top 100 highly expressed genes account for 58.25% of all 
mapped EV-mRNA read counts, whereas only 34.04% account for the top 100 
mapped mRNAs in the cells (Fig. 4b). This result suggests a specific enrichment of 
biologically significant mRNAs in EVs. The majority of these mRNAs (78 mRNAs) 
appear in both the top 100 of either the cellular- or EV-derived transcriptome, and 
many encode rather ubiquitous ribosomal proteins (Fig. 4c). The remaining top EV-
mRNAs (22 mRNAs) are mostly associated with oxidative phosphorylation and 
protein transport (Fig. 4d). In contrast, the cellular transcriptome is enriched with 
mRNAs required for essential cellular functions, such as glycolysis, cell motion and 
regulation of apoptosis (Fig. 4e). Taken together, these results indicate that even 
though EV-mRNA content mirrors the transcriptome of their donor cells, EVs exhibit 
a distinct pattern in distribution of mRNA abundance. These findings clearly indicate 
that mRNAs are selectively sorted into EVs, rather than randomly incorporated during 
vesicular trafficking and extracellular release.  
 
3.3. EVs are selectively enriched with a subset of mRNAs  
 
We assessed the relative abundance of mRNAs in cells and EVs to determine 
the types of mRNAs that are specifically enriched in EVs. Volcano plotting shows 
that 254 mRNAs are significantly (P < 0.05) more abundant (≥ two-fold) in EVs 
compared to the cells (Fig. 5a, Supplementary Table 2). The most highly enriched 
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EV-mRNAs (“Top 10”) are RAB13, ARRDC4, NEFM, IGIP, NET1, RASSF3, 
HMGN5, TRAK2, ESF1 and ZEB1, in descending order of fold enrichment.  
 
Bioinformatic analysis using the Ingenuity Pathway Analysis (IPA) revealed 
that cellular processes, such as RNA post-transcriptional modification, gene 
expression and cell-to-cell signaling and interaction, are strongly overrepresented in 
EV-mRNAs. On the other hand, the transcriptome of EVs is depleted of 2,192 cellular 
mRNAs that are selectively linked to essential cellular processes, such as cell death 
and survival and cellular growth and proliferation. Gene Ontology (GO) enrichment 
analyses demonstrate the specific depletion of organelle-specific (i.e. endoplasmic 
reticulum, Golgi apparatus, endosome) mRNAs from EVs suggesting a functional 
role not primarily linked to intracellular trafficking (Supplementary Fig. S1). On the 
other hand, based on IPA analysis EVs preferentially contain mRNAs that encode 
proteins involved in cell-to-cell communication in the bone and bone marrow 
microenvironment. These include the genes involved in the recruitment of osteoclasts 
(NFKBIB, PGF), priming of adipose cells (FGF1), as well as self-renewal and 
proliferative expansion of hematopoietic stem and progenitor cells (FLT3LG, IL18, 
HOXB7, CCND1, CCND2) (Fig. 5b). 
 
Among the 254 enriched EV-mRNAs, osteoblast-EVs contain 49 unique 
mRNAs that have not been previously detected in EVs secreted by other cells or 
present in body fluids (Fig. 5c) [32]. These novel mRNAs have gene ontology 
annotations related to zinc ion-binding (AGAP2, ZNF677, ZNF846), regulation of 
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transcription (BDP1, SOX11, TAF7L) and kinase activity (LPAR1, MAP3K13, ZEB2). 
Furthermore, we compared the enriched EV-mRNA dataset to the previously 
characterized protein content of these EVs [29]. For a limited number of mRNAs (18 
mRNAs), osteoblast-EVs contain the corresponding protein (Fig. 5d). Two of these 
are derived from osteoblast-EV specific mRNAs (HIST1H1E and LPAR1), whereas 
the remaining 16 proteins include ribonucleoproteins (HNRNPA1, HNRNPA3, 
HNRNPH3), translation initiation factors (EIF3A, EIF5B), histones (HIST1H2BH, 
HIST1H2BO) and others (MAP4K4, NAP1L1, NCL, PABPC1, RAB13, SEPT7, SET, 
ST13, YES1). It is important to note that all the exons are covered by significant reads 
for the majority of the EV-mRNAs, confirming the enrichment of full-length mRNAs 
inside EVs (Fig. 6a). 169 out of 254 enriched EV-mRNAs demonstrate full (100%) 
exon coverage, while only 33 mRNAs have less than 50% coverage. Read coverage is 
uniform across the exons of the highly abundant mRNAs overrepresented in EVs 
(Fig. 6b-e, Supplementary Fig. S2). Furthermore, the majority of the full-length 
enriched EV-mRNAs are of intermediate size (100 – 500 bp) (Fig. 6f).   
 
Next, we visualized log ratios of the normalized read counts for mRNAs from 
EVs versus cells relative to their mean abundance. The resulting MA plot compares 
the expression levels of the 254 mRNAs enriched by at least two-fold in EVs. 
Remarkably, RAB13 is both the most highly enriched and most abundant EV-mRNA 
that is selectively incorporated in EVs compared to the EV-producing osteoblasts 
(Fig. 7a). Furthermore, it is the only member of the Rab GTPase family with such a 
striking selective abundance in EVs, strongly suggesting that RAB13 is specifically 
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enriched in EVs (Fig. 7b). We evaluated the expression levels of RAB13 along with 
ATP5E, which shows similar cellular and vesicular abundances in sequencing analysis 
(Fig. 7c). Quantitative real-time PCR results confirm the significant enrichment of 
RAB13 in EVs, consistent with the sequencing data (Fig. 7d).  Using IPA, we 
investigated the molecular functions and canonical pathways associated with the 
RAB13 protein (Fig. 7e). We identified 26 proteins that are directly or indirectly 
coupled to the activity of RAB13. These proteins have molecular and cellular 
functions related to DNA replication, recombination and repair, cellular growth and 
proliferation, cellular assembly and organization, cell movement, and cell 
morphology. The main canonical pathways in which RAB13 participates are TGF-β 
signaling, cell cycle control of chromosomal replication and nucleotide excision 
repair pathway. In addition, several of these RAB13 associated proteins regulate the 
proliferation of stromal cells, chondrocytes, blood cells and tumor cells, which are 
precisely the potential target cells that physiologically interact with osteoblasts in the 
bone microenvironment. Taken together, our study is consistent with the broader 
concept that osteoblasts communicate with their surrounding cells by generating EVs 
that are actively loaded with specific bioactive molecules. This molecular cargo 
encompasses a selective group of mRNAs capable of providing defined regulatory 
signals to recipient cells.  
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4. Discussion 
 
The discovery of extracellular RNA (e.g. circulating RNA, EV-RNA) with 
regulatory functions has tremendous ramifications for both medical sciences and 
clinical applications. In this study, we reported the extensive profiling of mRNAs 
incorporated within EVs released by human osteoblasts. We showed that EVs to some 
degree contain the mRNA signature of their host cells while being selectively 
enriched with a unique set of mRNAs that may support intercellular communication. 
Our findings provide a major advancement in our understanding of EVs as a newly 
discovered mode of communication between osteoblasts and the surrounding 
microenvironment. 
 
We previously showed that osteoblasts secrete EVs containing a specific set of 
proteins important for their communication with their target cells [29]. Here, we 
investigated the mRNA profile of osteoblast-EVs to further characterize and discover 
the role of EVs in intercellular communication. Currently, the EV field is still 
challenged by variation in the reliability and procedural differences in EV-RNA 
isolation protocols [33, 34]. In our study, we reproducibly obtained satisfactory RNA 
yields with robust size distributions that were consistent between the different 
preparations. Bioanalyzer profiles of our total RNA preparations show that osteoblast-
EVs lack the typical cellular rRNAs and are enriched with small RNAs that range 
from 25 to 1,000 nucleotides, in accordance with other EV-RNA studies [35-37]. 
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Diverse cell types secrete small EV-RNAs that mainly consist of miRNAs and other 
small non-coding RNA molecules. Yet, there is increasing evidence showing the 
presence of functional mRNA specifically packaged inside EVs. However, intact 
mammalian mRNAs typically range between 400 and 12,000 nucleotides in length 
[38]. The smaller size range of osteoblast-EV-derived RNAs inevitably leads to the 
question whether EVs merely contain mRNA fragments. A report by Batagov and 
colleagues presented data indicating that EVs contain fragments derived from the 3'-
untranslated regions (3’-UTR) of certain mRNAs to protect the target mRNA against 
miRNA degradation [39]. On the other hand, our exon coverage analyses demonstrate 
that osteoblast-EVs are specifically enriched with full-length mRNAs of intermediate 
size. Several other studies reported the transfer of full-length EV-mRNA between 
cells with subsequent translation into functional proteins by the recipient cells [40-
42]. It is conceivable that cells may transmit both full-length mRNAs and 3’-UTR 
fragments as a two-pronged strategy that, first, instructs translation of proteins in the 
recipient cell, and second, relieves miRNA-mediated translation inhibition by 
competition with 3’-UTRs containing relevant miRNA binding sequences. 
 
Next-generation sequencing technologies have permitted comprehensive 
analyses of whole transcriptomes with single nucleotide resolution and quantitative 
assessments of RNA levels. We applied next-generation sequencing to identify RNA 
reads that correspond to 11,629 EV-mRNAs. The content and abundance profile of 
this mRNA set mirrors the mRNAs detected in donor cells. Because EVs may form 
by budding from the plasma membrane or exocytosis of multivesicular bodies, it is 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
 
 
 Morhayim et al. 
 
 
 
 
16 
possible that cellular components are non-specifically incorporated into EVs during 
their biogenesis. Indeed, many mRNAs present in EVs are similarly abundant in the 
cells that produce them suggesting that they are simply stochastically distributed into 
EVs. For example, mRNAs for ribosomal proteins are highly abundant in cells and 
also found in top 100 in EV-mRNAs. Nevertheless, there are a number of mRNAs 
that are either selectively enriched or depleted in EVs compared to the producing 
cells. The quantitative and qualitative differences in the transcriptome of EVs versus 
cells clearly suggest that at least some mRNAs may be specifically sorted and 
packaged into EVs to support cell–cell communication.  
 
Comparative transcriptome analyses reveal selective enrichment and depletion 
of particular mRNAs that are significantly overrepresented (254 mRNAs) or 
underrepresented (2,193 mRNAs) in EVs when compared to the producing cells. EVs 
appear to be specifically depleted of mRNAs required for vital cellular functions, yet 
many enriched EV-mRNAs encode proteins that directly or indirectly mediate mRNA 
translation by supporting the biogenesis of ribosomes (e.g., enzymes that mediate 
rRNA processing or structural ribosomal proteins). Because 18S and 28S rRNAs, 
which are two major constituents of the ribosome, are not detected in the total RNA 
distribution of EVs compared to that of cells and the abundance of mRNAs encoding 
a particular subset of ribosomal proteins may suggest a specific role in vesicular 
function. Consistent with our findings, previous studies reported that EVs contain 
mRNAs encoding ribosomal proteins, as well as elongation and translation factors [8, 
43]. Furthermore, Jenjaroenpun and colleagues suggested that these genes upon 
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translation in the recipient cells may provide essential ribosomal components to 
support the translation of other EV-mRNAs [44]. Previously, we showed that the 
stages of differentiation and the mineralization condition are also among the factors 
that influence the nature and abundance of EV cargo [29]. EVs secreted by 
mineralizing osteoblasts are enriched with biomineralization-related proteins 
indicating an activity associated with bone formation. On the other hand, the 
enrichment of ribosomal proteins as well as mRNAs that encode ribosomal proteins in 
EVs secreted by non-mineralizing osteoblasts brings diverse speculations on their role 
of stabilizing the miRNA cargo or transferring of ribosomal parts to facilitate gene 
expression in the target cells. At this stage, it is still challenging to distinguish the role 
of individual EV cargo. In light of our findings, we can conclude that regardless of the 
possibility that EV-mRNAs may be involved in very common cellular activities, the 
most interesting mRNA species are those that are less abundant, as well as fairly 
unique to EVs and not represented in the recipient cell.  
 
Crosstalk between osteoblasts and the surrounding bone microenvironment is 
critical to maintain essential biological processes, such as osteoclastogenesis, 
hematopoiesis and adipogenesis. Hence, a major objective of our studies is to identify 
unique mRNAs in EVs that could affect the biological state of the recipient cell. The 
majority of the mRNAs enriched in osteoblast-EVs are also detected in EV 
preparations from other cells and body fluids, suggesting that some of these mRNAs 
may have common functions related to generic activities of EVs, rather than specific 
biological roles linked to the bone microenvironment. However, a substantial subset 
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(~20%) of the enriched mRNAs is uniquely detected in osteoblast-EVs and thus can 
be attributed to a specific osteoblast-related and EV-mediated function. Enriched 
osteoblast-EV-mRNAs include those that encode proteins capable of regulating the 
fate of target neighboring cells in the bone microenvironment. Therefore, it is 
intriguing that such regulatory mRNAs are selectively sorted into osteoblast-EVs. We 
anticipate that further investigation of EV-specific mRNAs will permit delineation of 
the EV-mediated mechanisms by which osteoblasts communicate and control an 
intricate cell-to-cell interaction network in the bone microenvironment. 
 
The most strikingly overrepresented EV-mRNA is RAB13, because it is 
exceptionally abundant in EVs compared to the cells. RAB13 protein is a member of 
the Rab family of small GTPases, which are primarily involved in vesicle trafficking, 
including vesicle production and fusion at the target cell membrane [45]. 
Furthermore, even though our studies yielded very few examples in which mRNAs 
and their encoded proteins are co-packaged in EVs, osteoblasts-EVs not only contain 
RAB13 mRNA but also the RAB13 protein. RAB13 protein may have a role in EV 
biogenesis and cargo sorting at the donor cell membrane [29]. However, the 
enrichment of this mRNA in osteoblast-EVs and its putative transfer into recipient 
cells could represent a regulatory mechanism by which osteoblasts control EV 
production in their target cells. Beyond the latter possibility, Rab proteins also 
regulate cytoskeleton organization and assembly of tight junctions, and thereby 
regulate cell adhesion necessary for cell growth [46, 47]. Accordingly, our network 
analysis predicted potential RAB13 targets that play important roles in the 
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proliferation of chondrocytes, stromal, blood and tumor cells, indicative of a possible 
role in communication between osteoblasts and the target cells within the bone 
microenvironment.  
 
Osteoblasts are known to communicate with osteoclasts to coordinate tissue 
mineralization and resorption during bone remodeling. Intriguingly, Rab family 
proteins have essential roles in osteoclastic membrane trafficking required for bone 
resorption [48, 49]. RAB13, in particular, has been shown to be upregulated during 
osteoclast differentiation where it engages in vesicular trafficking events unrelated to 
bone resorption [50]. The possibility arises that osteoblasts could deliver RAB13 to 
immature osteoclasts via EVs to alter the osteoclast phenotype and perhaps provoke 
secondary extracellular signals emanating from osteoclasts.  A number of follow-up 
studies will be required to identify potential target cells of osteoblast-EVs, establish 
how EVs unload their cargo and determine how EVs affect the biological properties 
of recipient cells.  
 
In conclusion, in this study we present a comprehensive analysis of the EV 
transcriptome that suggests new mechanistic concepts. Our studies suggests a model 
in which EVs produced by osteoblasts may be part of a paracrine signaling system 
that coordinates the biological functions of both skeletal and hematopoietic cells in 
the bone microenvironment. Our results provide the molecular basis for understanding 
the biological significance of EV-mRNAs in the context of bone related processes. It 
remains to be elucidated whether EV-mRNAs are translated and consequently are 
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rendered functional upon delivery into the target cells. Finally, EV transcriptome-
profiling offers a potent avenue for discovery of non-invasive diagnostics for various 
diseases and facilitates the development of cell-free strategies for regenerative 
therapy.  
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FIGURE CAPTIONS 
 
Fig. 1. RNA profiling of human osteoblasts and osteoblast-EVs. (a-b) Representative 
Agilent 2100 Bioanalyzer electropherograms show the size distribution of total RNA 
extracted from (a) osteoblasts and (b) osteoblast-EVs (N = 3). Arrows show the 
characteristic cellular 18S (left) and 28S (right) rRNA peaks. FU, fluorescent units. s, 
seconds (time). 
 
Fig. 2. Flowchart of the mRNA-sequencing data analysis. Total cellular and EV-RNA 
was isolated using TRIzol® extraction method, and after poly-A tail selection with 
oligo(dT) primers the RNA was sequenced via high throughput next-generation 
sequencing (N = 3). Initially, the reads were mapped to human genome and then the 
read counts were normalized and converted to counts per million mapped reads 
(CPM), which were subsequently converted to reads per kilobase per million (RPKM) 
mapped reads using Edge R. The reads were further filtered to remove low quality 
reads (CPM ≤ 1 and RPKM ≤ 0.1). Only the transcripts that mapped to mRNAs, 
which were detected in all replicates were considered for further analysis. Highly 
abundant mRNA transcripts that were enriched in EVs compared to the donor 
osteoblasts were studied via volcano plot and MA plot analyses.  
 
 
Fig. 3. Next-generation sequencing mRNA profiling of osteoblast-EVs. (a) Scatter 
plot shows the correlation (R
2
: 0.731) of normalized read counts (average CPM) 
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33 
between cellular and EV transcripts (N = 3). (b) Pie chart shows the fraction of 
transcripts that were mapped to protein-coding mRNAs in EVs (91.80%, dark gray). 
Cellular mRNA percentage is shown in brackets. (c) Classification of the detected 
cellular and EV-mRNAs shows the fraction (%) of mRNAs that encode proteins 
involved in diverse biological functions determined by IPA analysis. 
 
Fig. 4. The most abundant cellular and EV-mRNAs. (a) Venn diagram shows the 
distribution of mRNAs between osteoblasts and EVs. (b) Top 100 most abundant 
mRNAs make up more than 50% of the total RPKM values for EVs. (c) Top 100 EV-
mRNAs are mostly annotated to genes encoding for proteins involved in protein 
synthesis and RNA processing. (d-e) RPKM values of the representative top 100 (d) 
EV-mRNAs (mean ± SD) (N = 3) and (e) cellular RNAs (mean ± SD) (N = 3).  
 
Fig. 5. Selectively enriched EV-mRNAs. (a) Volcano plot (significance versus fold 
change) shows the significantly (P < 0.05, compared with osteoblasts by Student’s t-
test) abundant  (≥ two-fold; 254 mRNAs; right) and depleted (≤ 0.5-fold; 2192 
mRNAs; left) EV-mRNAs based on CPM values (N = 3). The top 10 most enriched 
EV-mRNAs are highlighted in blue. (b) Fold change distribution of selected genes 
annotated to overrepresented biological processes, such as induction of proliferation 
and expansion of hematopoietic stem and progenitor cells (HSPCs), recruitment of 
osteoclasts, and priming of adipocytes, identified by IPA (mean ± SD) (N = 3). (c) 
Venn diagram shows the number of unique mRNAs detected in osteoblast-EVs in 
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comparison with Vesiclepedia. (d) Venn diagram shows the overlap between the EV-
protein and -mRNA content. 
 
Fig. 6. Exon coverage of EV-mRNAs. (a) The number of EV-mRNAs and the 
corresponding fraction of exons that are covered with reads for a given mRNA 
compared to the cells. (b-e) The distribution of read counts (RPKM) across the 
different exons of selected enriched EV-mRNAs in EVs (black solid line) and cells 
(gray dotted line) (mean ± SD) (N = 3). f) Length (bp; base pairs) distribution of full-
length (100% exon coverage) enriched EV-mRNAs.   
 
Fig. 7. EVs are selectively enriched with RAB13 mRNA. (a) MA plot (fold change 
versus abundance) shows the RPKM values of the significantly enriched EV-mRNAs. 
RAB13 is both the most enriched and abundant mRNA detected in EVs.(b) MA plot 
of the Rab family mRNAs detected in both cells and EVs. RAB13 is the only Rab 
family mRNA that is highly enriched in EVs compared to the donor osteoblasts. (c-d) 
Relative expressions of RAB13 and ATP5E in EVs and cells by (c) mRNA-
sequencing (mean ± SD) (N = 3) and (d) qPCR (mean ± SD) (N = 6). The mRNA-
sequencing results are shown as average fold change of RPKM values relative to 
GAPDH. The qPCR results are normalized to average GAPDH expression.  (e) IPA 
interaction network shows the predicted biological functions (gray) associated with 
the downstream targets (black) of RAB13 protein. * P < 0.05, compared with cells by 
Student’s t-test; ns, not significant. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4  
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Figure 5 
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Figure 6 
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Figure 7 
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Highlights  
 
 Osteoblasts secrete nano-sized EVs packaged with regulatory mRNA  
 Global expression profiles of parental cells and EVs confirm selective mRNA 
sorting  
 EVs are specifically depleted of mRNAs essential for basic cellular activities  
 Overrepresented EV-mRNAs are associated with protein translation and RNA 
processing 
